Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNRNP200 | O75643 | 3/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 5/20 | 0.45 |
| ▸ | MAOA | P21397 | 4/20 | 0.45 |
| ▸ | NAAA | Q02083 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | LIPC | P11150 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625864 | 0.88 | MAOA (0.44) | MAOBMAOANAAAL3MBTL1 | |
| SCHEMBL2784147 | 0.79 | NPC1 (0.51) | MAOBMAOA | |
| SCHEMBL3626606 | 0.78 | HSD11B1 (0.45) | NAAA | |
| SCHEMBL3625862 | 0.78 | SNRNP200 (0.50) | SNRNP200MAOBMAOAL3MBTL1 | |
| SCHEMBL3550361 | 0.75 | HIF1A (0.46) | NAAA | |
| SCHEMBL5737605 | 0.74 | GRM5 (0.59) | SNRNP200GRM5GRIN1ALOX5MAOB | |
| SCHEMBL11227524 | 0.73 | MAOA (0.61) | GRM5MAOBMAOA | |
| SCHEMBL22750386 | 0.71 | ALOX5 (0.67) | SNRNP200GRM5ALOX5MAOBMAOA | |
| SCHEMBL29508690 | 0.71 | ALOX5 (0.67) | SNRNP200GRM5ALOX5MAOBMAOA | |
| SCHEMBL13097411 | 0.71 | GRM5 (0.56) | SNRNP200GRM5ALOX5MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795251-B2 | 3,4-dihydro-benzo[e][1,3]oxazin-2-ones | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-1874742-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108671-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | CYP2C8, CYP2C18, CYP4B1 | SNRNP200 4674/4885GRM5 866/4885GRIN1 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.